Anti-angiogenic effects of a mutant endostatin: A new prospect for treating retinal and choroidal neovascularization

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Bai, Yujing ^a   Zhao, Min ^a   Zhang, Chunfang ^a   Li, Shanshan ^a   Qi, Yun ^a   Wang, Bin ^a   Huang, Lvzhen ^a   Li, Xiaoxin ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOSTATIN; MUTANT ENDOSTATIN; POLYETHYLENE GLYCOL PROPIONALDEHYDE COVALENT MUTANT ENDOSTATIN; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; MACROGOL DERIVATIVE; VASCULOTROPIN A;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CAPILLARY ENDOTHELIAL CELL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR CLONING; MOUSE; NEWBORN; NONHUMAN; OXYGEN-INDUCED RETINOPATHY; RABBIT; SUBRETINAL NEOVASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL; ANGIOGENESIS; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL MOTION; CHEMISTRY; CHOROIDAL NEOVASCULARIZATION; CYTOLOGY; DRUG EFFECTS; ENDOTHELIUM CELL; GENETICS; METABOLISM; MOLECULAR GENETICS; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; NUCLEOTIDE SEQUENCE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA; RETINA BLOOD VESSEL; RETINA DISEASE; RETINAL NEOVASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BASE SEQUENCE; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHOROIDAL NEOVASCULARIZATION; ENDOSTATINS; ENDOTHELIAL CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; POLYETHYLENE GLYCOLS; RABBITS; RETINA; RETINAL DISEASES; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84911866851     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112448     Document Type: Article

References (35)

1. Zhang SX, Ma JX (2007) Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy. Prog Retin Eye Res 26: 1-37.
2. Bressler SB (2009) Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmology 116: S1-7.
3. Fulton AB, Hansen RM, Moskowitz A, Akula JD (2009) The neurovascular retina in retinopathy of prematurity. Prog Retin Eye Res 28: 452-482.
4. Montero JA, Ruiz-Moreno JM (2010) Treatment of choroidal neovascularization in high myopia. Curr Drug Targets 11: 630-644.
5. Shultz RW, Bakri SJ (2011) Treatment for submacular hemorrhage associated with neovascular age-related macular degeneration. Semin Ophthalmol 26: 361-371.
6. Jager RD, Mieler WF, Miller JW (2008) Age-related macular degeneration. N Engl J Med 358: 2606-2617.
7. Folkman J (1996) Endogenous inhibitors of angiogenesis. Harvey Lect 92: 65-82.
8. Karamouzis MV, Moschos SJ (2009) The use of endostatin in the treatment ofsolid tumors. Expert Opin Biol Ther 9: 641-648.
9. Karamouzis MV, Moschos SJ (2009) The use of endostatin in the treatment ofsolid tumors. Expert Opin Biol Ther 9: 641-648.
10. Reddy KR (2000) Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann Pharmacother 34: 915-923.
11. Yowell SL, Blackwell S (2002) Novel effects with polyethylene glycol modified pharmaceuticals. Cancer Treat Rev 28 Suppl A: 3-6.
12. Chaffee S, Mary A, Stiehm ER, Girault D, Fischer A, et al. (1992) IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. J Clin Invest 89: 1643-1651.
13. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805-2816.
14. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, et al. (2000) Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343:1666-1672
15. Bai YJ, Huang LZ, Zhou AY, Zhao M, Yu WZ, et al. (2013) Antiangiogenesis effects of endostatin in retinal neovascularization. J Ocul Pharmacol Ther 29: 619-626
16. Yu WZ, Li XX, She HC, He PY, Dong JQ, et al. (2003) Gene transfer of kringle 5 of plasminogen by electroporation inhibits corneal neovascularization. Ophthalmic Res 35: 239-246.
17. Wang F, Bai Y, Yu W, Han N, Huang L, et al. (2013) Anti-angiogenic effect of KH902 on retinal neovascularization. Graefes Arch Clin Exp Ophthalmol 251: 2131-2139.
18. Bai YJ, Huang LZ, Xu XL, Du W, Zhou AY, et al. (2012) Polyethylene glycolmodified pigment epithelial-derived factor: new prospects for treatment of retinal neovascularization. J Pharmacol Exp Ther 342: 131-139.
19. Neely KA, Gardner TW (1998) Ocular neovascularization: clarifying complex interactions. Am J Pathol 153: 665-670.
20. Barkmeier AJ, Carvounis PE (2011) Retinal pigment epithelial tears and the management of exudative age-related macular degeneration. Semin Ophthalmol 26: 94-103.
21. Campochiaro PA (2013) Ocular neovascularization. J Mol Med (Berl) 91: 311- 321.
22. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, et al. (2008) Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 27: 331- 371.
23. Cao Y, Arbiser J, D'Amato RJ, D'Amore PA, Ingber DE, et al. (2011) Forty-year journey of angiogenesis translational research. Sci Transl Med 3: 114rv113.
24. Avery RL (2013) What is the evidence for systemic effects of intravitreal anti- VEGF agents, and should we be concerned? Br J Ophthalmol.
25. Doguizi S, Ozdek S (2013) PIGMENT EPITHELIAL TEARS ASSOCIATED WITH ANTI-VEGF THERAPY: Incidence, Long-term Visual Outcome, and Relationship with Pigment Epithelial Detachment in Age-related Macular Degeneration. Retina.
26. Quaggin SE (2012) Turning a blind eye to anti-VEGF toxicities. J Clin Invest 122: 3849-3851.
27. Fujita Y, Abe R, Shimizu H (2008) Clinical approaches toward tumor angiogenesis: past, present and future. Curr Pharm Des 14: 3820-3834.
28. Abdollahi A, Hlatky L, Huber PE (2005) Endostatin: the logic of antiangiogenic therapy. Drug Resist Updat 8: 59-74.
29. Haller JA (2013) Current anti-vascular endothelial growth factor dosing regimens: benefits and burden. Ophthalmology 120: S3-7.
30. .Xu HL, Tan HN, Wang FS, Tang W (2008) Research advances of endostatin and its short internal fragments. Curr Protein Pept Sci 9: 275-283.
31. .Boehm T, O'Reilly MS, Keough K, Shiloach J, Shapiro R, et al. (1998) Zincbinding of endostatin is essential for its antiangiogenic activity. Biochem Biophys Res Commun 252: 190-194.
32. Abuchowski A, McCoy JR, Palczuk NC, van Es T, Davis FF (1977) Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 252: 3582-3586.
33. Pai SS, Tilton RD, Przybycien TM (2009) Poly(ethylene glycol)-modified proteins: implications for poly(lactide-co-glycolide)-based microsphere delivery. AAPS J 11: 88-98.
34. Chapman AP (2002) PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 54: 531-545.
35. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, et al. (2007) Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114: 2179-2182.